MARKET

XNCR

XNCR

Xencor
NASDAQ
9.32
-0.01
-0.11%
Opening 10:39 07/10 EDT
OPEN
9.33
PREV CLOSE
9.33
HIGH
9.35
LOW
9.13
VOLUME
46.40K
TURNOVER
--
52 WEEK HIGH
27.24
52 WEEK LOW
7.16
MARKET CAP
663.31M
P/E (TTM)
-2.9474
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XNCR last week (0630-0704)?
Weekly Report · 3d ago
Weekly Report: what happened at XNCR last week (0623-0627)?
Weekly Report · 06/30 10:10
Xencor’s Promising Developments in Autoimmune and Oncology Drive Buy Rating
TipRanks · 06/24 19:55
Weekly Report: what happened at XNCR last week (0616-0620)?
Weekly Report · 06/23 10:07
Incyte granted FDA label expansion for lymphoma therapy Monjuvi
Seeking Alpha · 06/18 20:03
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward
Seeking Alpha · 06/18 18:58
Insider Sale: Director at $XNCR Sells 2,993 Shares
NASDAQ · 06/16 23:30
Weekly Report: what happened at XNCR last week (0609-0613)?
Weekly Report · 06/16 10:10
More
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Webull offers Xencor Inc stock information, including NASDAQ: XNCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XNCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XNCR stock methods without spending real money on the virtual paper trading platform.